Nanocarrier targets enzyme to help heart repair after injury

An acid-responsive nanocarrier delivers siENO1 to macrophages to reduce inflammation.

Myocardial infarction (MI) causes persistent inflammatory dysregulation. This happens when macrophages undergo glycolytic reprogramming and adopt an inflammatory phenotype.

The enzyme enolase 1 (ENO1) is up-regulated in post-MI macrophages. ENO1 is a critical regulator of macrophage metabolic fate and inflammatory function.

Engineers created an acid-responsive nanocarrier called PECS. This carrier externalizes phosphatidylserine within the acidic infarct microenvironment to help selective macrophage uptake.

The PECS-loaded siENO1 (siENO1@PECS) treatment suppressed glycolytic flux. This reduced lactate accumulation and relieved its metabolic inhibition of KLF4 to initiate anti-inflammatory reprogramming.

In vivo treatment attenuated infarct size, fibrosis, and cardiomyocyte apoptosis. It also improved ventricular function.

Key facts

  • ENO1 is a glycolytic enzyme that regulates macrophage inflammatory function.
  • The PECS nanocarrier responds to the acidic infarct microenvironment.
  • siENO1@PECS treatment improves ventricular function and reduces fibrosis.

All sections

Edition